Showing results (101-110 of 777) with videos related to
Sort By:
Pageof 78
Oncogene|February 7, 2020
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myelomaArghya Ray, Yan Song, Ting Du, et al.Current Drug Targets|November 1, 2006
Proteasome inhibition as a new therapeutic principle in hematological malignanciesConstantine S Mitsiades, Nicholas Mitsiades, Teru Hideshima, et al.Essays in Biochemistry|October 28, 2005
Proteasome inhibitors as therapeuticsConstantine S Mitsiades, Nicholas Mitsiades, Teru Hideshima, et al.Cancer Research|December 3, 2004
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myelomaLaurence Catley, Yu-Tzu Tai, Reshma Shringarpure, et al.Cancer Research|February 20, 2007
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myelomaKlaus Podar, Marc S Raab, Giovanni Tonon, et al.Molecular Cancer Therapeutics|June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cellsTanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma modelPaola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.Blood|December 14, 2002
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arraysDharminder Chauhan, Guilan Li, Daniel Auclair, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Aaron N Nguyen, et al.Blood|August 21, 2004
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.Pageof 78